ScreenerHero

FBIOFortress Biotech, Inc.

NAS · US · Healthcare · Biotechnology · fortressbiotech.com
2.870USD+0.70%Mkt Cap: 95.72M $P/E: 1.04

Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule fo…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap95.72M $
Enterprise Value-8.93M $
Revenue (TTM)68.47M $
Gross Profit42.34M $
Net Income (TTM)6.82M $
Revenue/Share2.252 USD
Last Price2.870 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees78
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)1.04
P/E (Forward)-1.57
PEG—
EV/EBITDA0.36
EV/Revenue-0.13
P/S1.35
P/B0.56
EPS (TTM)2.70
EPS (Forward)-1.76
52W Range
1.99035% of range4.530
52W High4.530 USD
52W Low1.990 USD
Profitability
Gross Margin66.92%
Oper. Margin-53.46%
EBITDA Margin-35.90%
Profit Margin10.77%
ROE13.66%
ROA3.67%
Growth
Revenue Growth14.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-65.78M $
CapEx (TTM)—
FCF Margin-24.66%
FCF Yield-17.64%
Net Debt-143.26M $
Net Debt/EBITDA5.83
Balance Sheet
Debt/Equity1.49
Current Ratio3.96
Quick Ratio3.76
Book Value/Sh4.927 USD
Cash/Share5.894 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:15
Split DateOct 10, 2023
Analyst Consensus
Rating—
Target (Mean)11.00 USD
Upside (mean)+283.3%
Target Range5.000 USD – 17.00 USD
$5.000+283.3% to mean$17.00
# Analysts2
Ownership
Shares Out.33.35M
Float23.22M
Insiders22.70%
Institutions26.11%
Short Interest
Short Ratio10.5d
Short % Float22.55%
Short % Out.17.41%
Shares Short5.78M
Short (prev mo.)5.31M
Technical
SMA 503.064 (-6.3%)
SMA 2002.995 (-4.2%)
Beta1.21
S&P 52W Chg18.16%
Avg Vol (30d)719.57K
Avg Vol (10d)746.45K
Technical Indicators
RSI (14)46.2
MACD-0.0875
MACD Signal-0.0827
MACD Hist.-0.0048
BB Upper3.522 USD
BB Middle2.974 USD
BB Lower2.425 USD
BB Width36.92%
ATR (14)0.2058 USD
Vol Ratio (20d)0.28x